Not all bad: Drug-induced interstitial pneumonia in DLBCL patients is potentially fatal but could be linked to better survival-Reference-Cited by-同舟云学术

Not all bad: Drug-induced interstitial pneumonia in DLBCL patients is potentially fatal but could be linked to better survival

Published:2021-12 Issue: Volume:111 Page:106688
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Wei Wen^ORCID,Zhu Yajie,Tang Jianning,Xu Chuan,Li Jiman,He Shuya,Zhang Zhihui,Wu Ping,Luo Lei,Guo Qin,Li Fang,Ren Yuanrong,Yu Sisi,Li Renqin,Li Li^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference30 articles.

1. Interstitial pneumonitis related to rituximab therapy;Burton;N. Engl. J. Med.,2003

2. Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab;Lim;Korean J. Intern. Med.,2010

3. Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma;Huang;Ann. Hematol.,2011

4. Immunochemotherapeutic increase of peripheral absolute monocyte count predicts interstitial pneumonia in lymphoma patients;Lang;Hematol. Oncol.,2018

5. Non-infectious pulmonary toxicity of rituximab: a systematic review;Hadjinicolaou;Rheumatology,2011

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug‐induced pneumonitis risk in diffuse large B‐cell/follicular lymphoma patients treated with R‐CHOP‐like regimen is associated with the use of granulocyte colony‐stimulating growth factors;Cancer Medicine;2024-01

2. A case of diffuse large B-cell lymphoma with interstitial pneumonia;Cancer Pathogenesis and Therapy;2023-07

3. A novel Gboxin analog induces OXPHOS inhibition and mitochondrial dysfunction-mediated apoptosis in diffuse large B-cell lymphoma;Bioorganic Chemistry;2022-10

4. Meta-Analysis of Risk Factors and Incidence of Interstitial Pneumonia With CHOP-Like Regimens for Non-Hodgkin Lymphoma;Frontiers in Oncology;2022-06-01

5. Antineoplastics;Reactions Weekly;2022-04